Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis
Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis
复制标题
喹硫平和氯氮平治疗多巴胺能精神病帕金森病患者
DOI：
--
复制
发表时间：
2004
影响因子：
1
通讯作者：
A. Quattrone
中科院分区：
文献类型：
--
作者：
L. Morgante;A. Epifanio;E. Spina;M. Zappia;A. D. Di Rosa;R. Marconi;G. Basile;Giorgio Di Raimondo;P. La Spina;A. Quattrone
本研究旨在通过一项随机、开放、盲法、平行组试验，比较奎替鲁与氯氮平治疗帕金森病伴多巴胺能精神病患者的疗效和安全性。方法45例帕金森病（PD）合并抗帕金森病药物所致精神病患者随机分为奎替鲁胺组和氯氮平组。试验持续时间为12周。40例患者（每个治疗组20例）完成了研究。奎替利末次剂量（平均值±标准差）为91 ± 47 mg/d，氯氮平末次剂量为26 ± 12 mg/d。采用简明精神病评定量表（BPRS）和临床总体印象量表-严重程度子量表（CGI-S）评估精神病的严重程度。在研究期间，使用统一帕金森氏病评定量表（UMRS）III评估运动状况。采用异常不自主运动量表（AIMS）评估运动障碍。结果40例患者完成了研究，其中20例服用氯氮平，20例服用奎替卡松。两个治疗组的精神病理状态较基线均显著改善（P < 0.001）。在任何评估时间，氯氮平和奎替利之间均无差异。运动条件保持不变后，氯氮平和奎替利。两组运动障碍均明显减少（P < 0.05）。副作用轻微，通常是短暂的，耐受性良好。结论奎替鲁与氯氮平治疗PD患者多巴胺能精神病疗效相当。
ObjectiveThis study aimed to compare the efficacy and safety of quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis in a randomized, open-label, blinded-rater, parallel group trial. MethodsForty-five patients with Parkinson disease (PD) and psychosis induced by antiparkinsonian drugs were randomly assigned to receive either quetiapine or clozapine. The duration of the trial was 12 weeks. Forty patients, 20 in each treatment group, completed the study. The final dose of quetiapine (mean ± SD) was 91 ± 47 mg/d and that of clozapine 26 ± 12 mg/d. The severity of psychosis was assessed using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale–Severity Subscale (CGI-S). The Unified Parkinson’s Disease Rating Scale (UPDRS) III was used to assess motor conditions during the study period. The Abnormal Involuntary Movement Scale (AIMS) was performed to evaluate dyskinesias. ResultsForty patients, 20 on clozapine and 20 on quetiapine, completed the study. The psychopathologic state improved significantly (P < 0.001) from baseline in both treatment groups. No differences were found between clozapine and quetiapine at any assessment time. Motor conditions remained unchanged after clozapine and quetiapine. Dyskinesias decreased significantly (P < 0.05) in both groups. Side effects were mild, generally transient, and well tolerated. ConclusionsQuetiapine and clozapine appear equally efficacious for treatment of dopaminergic psychosis in patients with PD.
精神安定药的临床前药理学：关注新一代化合物。
DOI：
--
发表时间：
1996
期刊：
The Journal of clinical psychiatry.
影响因子：
--
作者：
Richelson,E
通讯作者：
Richelson,E
氯氮平和利培酮治疗帕金森病精神病。
DOI：
10.1176/jnp.12.3.364
发表时间：
2000
期刊：
The Journal of neuropsychiatry and clinical neurosciences.
影响因子：
--
作者：
Ellis,T;Cudkowicz,ME;Sexton,PM;Growdon,JH
通讯作者：
Growdon,JH